YnnoMed is a drug R&D platform committed to helping those suffering from drug-resistant infections by developing first-in-class antimicrobials with new modes-of-action. YnnoMed has pioneered the development of bacterial transcription inhibitors as new antimicrobial agents. The deployment of our in-house AI-assisted technology significantly shortens time, streamlines processes, and ultimately reduces costs and failure rates involved in pre-clinical stages of drug development. The result is several series of patent-protected first-in-class antibiotic pipelines with proven effectiveness against drug-resistant pathogens found on the WHO priority pathogens list, which show strong prospects for clinical use. Working closely with our international partners, we seek to turn the tide of antimicrobial resistance by marketising “Made in Hong Kong” first-in-class antibiotics and by inspiring other key players to embrace revolutionary approaches to drive availability of new drugs and enhance the global pipeline.

Founder(s) Name(s)

• Prof. MA Cong (Associate Professor, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University)
• Prof. YANG Xiao (The Chinese University of Hong Kong)
  
  

Achievement(s)

• Global Innovation Award at TechConnect World Innovation Conference and Expo 2019
• Winner of Science Breakthrough of the Year 2023 (Science Start-up)  by Falling Walls Foundation
• Bronze Medal at the International Exhibition of Inventions Geneva 2023
• Champion of Elevator Pitch Competition at CUHK Innovation Day 2022

Patent(s)

• US Patent 11,479,529 B2
• EP Patent 3 737 664 A4
• CN Patent 111971271 A
• JP Patent 2021-510143 A
• US Patent 2022/0388953 A1
• CN Patent 112638909 A

Funding Support

• Supported by Technology Start-up Support Scheme for Universities (TSSSU)(2022/2023)&(2023/2024)
• Supported by HKSTP Incu-Bio Programme